Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials

Clinical Cardiology

Volumn 36, Issue 8, 2013, Pages

  Su, Qiang ^a   Li, Lang ^a   Liu, Yangchun ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VERAPAMIL;

ACUTE CORONARY SYNDROME; COCHRANE LIBRARY; CORONARY ARTERY; CORRECTED THROMBOLYSIS IN MYOCARDIAL INFARCTION FRAME COUNT; DATA ANALYSIS SOFTWARE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; EMBASE; HEART DISEASE; HEART INDEX; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE PERFUSION; HEART VENTRICLE WALL MOTION; HOSPITALIZATION; HUMAN; INCIDENCE; MEDLINE; META ANALYSIS; NO REFLOW PHENOMENON; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; TIMI MYOCARDIAL PERFUSION GRADE; TREATMENT DURATION; TREATMENT OUTCOME; WALL MOTION INDEX;

ACUTE CORONARY SYNDROME; CALCIUM CHANNEL BLOCKERS; CHI-SQUARE DISTRIBUTION; CORONARY CIRCULATION; CORONARY VESSELS; HUMANS; INJECTIONS, INTRA-ARTERIAL; NO-REFLOW PHENOMENON; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VERAPAMIL;

EID: 84882265171     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22143     Document Type: Review

References (21)

1. Dong-bao L, Qi H, Zhi L, et al. Predictors and long-term prognosis of angiographic slow/no-reflow phenomenon during emergency percutaneous coronary intervention for ST-elevated acute myocardial infarction. Clin Cardiol. 2010; 33: E7-E12.
2. Chen Y, Yang Y,. No-reflow phenomenon during percutaneous coronary intervention. Adv Cardiovasc Dis. 2005; 26: 5.
3. Porto I, Ashar V, Mitchell AR,. Pharmacological management of no-reflow during percutaneous coronary intervention. Curr Vasc Pharmacol. 2006; 4: 95-100.
4. Werner GS, Lang K, Kunhnert H, et al. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv. 2002; 57: 444-451.
5. Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Oxford, UK: Cochrane Collaboration; 2008.
6. Huang D, Qian J, Ge L, et al. Restoration of coronary flow in patients with no-reflow after primary coronary intervention of acute myocardial infarction (RECOVER). Am Heart J. 2012; 164: 394-401.
7. Zhang H, Cao Y, Wu Z, et al. Effect of intracoronary verapamil on no-reflow during percutaneous coronary intervention. Shangdong Med J. 2010; 50: 23.
8. Hendler A, Aronovich A, Kaluski E, et al. Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIMI 3 flow. J Invasive Cardiol. 2006; 18: 32-36.
9. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. 1997; 30: 1193-1199.
10. Vijayalakshmi K, Whittaker VJ, Kunadian B, et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006; 92: 1278-1284.
11. Qiao Z, Pu J, Ding S, et al. Effect of intracoronary verapamil on coronary flow, myocardial perfusion and clinical outcome during percutaneous coronary intervention for acute myocardial infarction. Chin J Intervent Cardiol. 2009; 17: 6.
12. Wu M, Ye Z,. Clinical efficacy and safety of intracoronary verapamil during percutaneous coronary intervention in patients with acute coronary syndromes. Chin J Geriatr. 2012; 31: 4.
13. Hang CL, Wang CP, Yip HK, et al. Early administration of intracoronary verapamil improves myocardial perfusion during percutaneous coronary interventions for acute myocardial infarction. Chest. 2005; 128: 2593-2598.
14. Movahed MR, Butman SM,. The pathogenesis and treatment of no-flow occurring during percutaneous coronary intervention. Cardiovasc Revasc Med. 2008; 9: 56-61.
15. Micari A, Belcik TA, Balcells EA, et al. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol. 2005; 96: 1410-1415.
16. Forman MB, Jackson EK,. Importance of tissue perfusion in ST segment elevation myocardial infarction patients undergoing reperfusion strategies: role of adenosine. Clin Cardiol. 2007; 30: 583-585.
17. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation. 2000; 101: 239-243.
18. Marzilli M, Orsini E, Marraccini P, et al. Beneficial effects of intracoronary adenosine as adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000; 101: 2154-2159.
19. Barcin C, Denktas AE, Lennon RJ, et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv. 2004; 61: 484-491
20. Hillegass WB, Dean NA, Liao L, et al. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol. 2001; 37: 1335-1343.
21. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Catheter Cardiovasc Diagn. 1996; 39: 113-118.